Search research articles
Contact Us
Filters
Showing results (1-10 of 80) with videos related to
Page
of 8
Sort By:
JAMA Oncology
|
April 10, 2020
The Mystic Role of Tumor Mutational Burden in Selecting Patients With Lung Cancer for First-Line Immunotherapy
Saiama N Waqar, Ramaswamy Govindan
Journal of Thoracic Disease
|
January 10, 2017
Precision medicine in lung cancer: the battle continues
Saiama N Waqar, Daniel Morgensztern
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 8, 2024
Novel Therapies in Cancer: Trials and Tribulations
Saiama N Waqar, Ramaswamy Govindan
JAMA Oncology
|
September 4, 2020
Demystifying the Role of Tumor Mutational Burden for Immunotherapy Selection-Reply
Saiama N Waqar, Ramaswamy Govindan
The Lancet. Oncology
|
November 11, 2018
Lorlatinib: a new-generation drug for ALK-positive NSCLC
Saiama N Waqar, Daniel Morgensztern
Expert Review of Clinical Immunology
|
June 9, 2015
Immunotherapy for non-small cell lung cancer: are we on the cusp of a new era?
Saiama N Waqar, Daniel Morgensztern
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 8, 2021
Adjuvant Therapy With EGFR Tyrosine Kinase Inhibitors: Tempering Great Expectations With Realism
Saiama N Waqar, Ramaswamy Govindan
Pharmacology & Therapeutics
|
June 6, 2017
Treatment advances in small cell lung cancer (SCLC)
Saiama N Waqar, Daniel Morgensztern
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
April 23, 2015
MET Mutation Associated with Responsiveness to Crizotinib
Saiama N Waqar, Daniel Morgensztern, Jennifer Sehn
Journal of Thoracic Disease
|
September 14, 2016
Role for adjuvant chemotherapy in patients with resected small cell lung cancer
Lingling Du, Saiama N Waqar, Daniel Morgensztern
Page
of 8
Search research articles
Search
Showing results (1-10 of 80) with videos related to
Sort By:
Page
of 8
JAMA Oncology
|
April 10, 2020
The Mystic Role of Tumor Mutational Burden in Selecting Patients With Lung Cancer for First-Line Immunotherapy
Saiama N Waqar, Ramaswamy Govindan
Journal of Thoracic Disease
|
January 10, 2017
Precision medicine in lung cancer: the battle continues
Saiama N Waqar, Daniel Morgensztern
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 8, 2024
Novel Therapies in Cancer: Trials and Tribulations
Saiama N Waqar, Ramaswamy Govindan
JAMA Oncology
|
September 4, 2020
Demystifying the Role of Tumor Mutational Burden for Immunotherapy Selection-Reply
Saiama N Waqar, Ramaswamy Govindan
The Lancet. Oncology
|
November 11, 2018
Lorlatinib: a new-generation drug for ALK-positive NSCLC
Saiama N Waqar, Daniel Morgensztern
Expert Review of Clinical Immunology
|
June 9, 2015
Immunotherapy for non-small cell lung cancer: are we on the cusp of a new era?
Saiama N Waqar, Daniel Morgensztern
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 8, 2021
Adjuvant Therapy With EGFR Tyrosine Kinase Inhibitors: Tempering Great Expectations With Realism
Saiama N Waqar, Ramaswamy Govindan
Pharmacology & Therapeutics
|
June 6, 2017
Treatment advances in small cell lung cancer (SCLC)
Saiama N Waqar, Daniel Morgensztern
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
April 23, 2015
MET Mutation Associated with Responsiveness to Crizotinib
Saiama N Waqar, Daniel Morgensztern, Jennifer Sehn
Journal of Thoracic Disease
|
September 14, 2016
Role for adjuvant chemotherapy in patients with resected small cell lung cancer
Lingling Du, Saiama N Waqar, Daniel Morgensztern
Page
of 8